Diffuse large B-cell lymphoma (DLBCL) with extra nodal skeletal involvement is rare. It is currently unclear whether these lymphomas should be treated in the same manner as those without skeletal involvement. We retrospectively analyzed the impact of combining high-dose methotrexate (HD-MTX) with an anthracycline-based regimen and rituximab as first-line treatment in a cohort of 93 patients with DLBCL and skeletal involvement with long follow-up. Fifty patients (54%) received upfront HD-MTX for prophylaxis of CNS recurrence (high IPI score and/or epidural involvement) or because of skeletal involvement. After adjusting for age, ECOG, high LDH levels, and type of skeletal involvement, HD-MTX was associated with an improved PFS and OS (HR: 0.2, 95% CI: 0.1-0.3, < 0.001 and HR: 0.1, 95% CI: 0.04-0.3, < 0.001, respectively). Patients who received HD-MTX had significantly better 5-year PFS and OS (77% vs. 39%, <0.001 and 83 vs. 58%, < 0.001). Radiotherapy was associated with an improved 5-year PFS (74 vs. 48%, = 0.02), whereas 5-year OS was not significantly different (79% vs. 66%, = 0.09). A landmark analysis showed that autologous stem cell transplantation was not associated with improved PFS or OS. The combination of high-dose methotrexate and an anthracycline-based immunochemotherapy is associated with an improved outcome in patients with DLBCL and skeletal involvement and should be confirmed in prospective trials.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8231126PMC
http://dx.doi.org/10.3390/cancers13122945DOI Listing

Publication Analysis

Top Keywords

skeletal involvement
24
high-dose methotrexate
8
diffuse large
8
large b-cell
8
b-cell lymphoma
8
involvement
7
skeletal
6
impact high-dose
4
methotrexate outcome
4
patients
4

Similar Publications

This study assessed the feasibility of miR17 ~ 92-based antiresorptive strategy by determining the effects of conditional transgenic (cTG) overexpression of miR17 ~ 92 in myeloid cells on bone and osteoclasts. Osteoclasts of male and female cTG mutant mice each showed 3- to fivefold overexpression of miR17 ~ 92 cluster genes compared to those of age- and sex-matched wildtype (WT) littermates. Male but not female cTG mutant mice had more trabecular and cortical bones as well as lower bone resorption reflected by reduction in osteoclast number and resorbing surface.

View Article and Find Full Text PDF

Bone Disease Associated with Inactivating Aromatase Mutations and its Management.

Calcif Tissue Int

January 2025

Department of Medicine, Surgery and Neurosciences, University of Siena, Policlinico Santa Maria Alle Scotte, Siena, Italy.

Aromatase deficiency (ORPHA:91; OMIM: 613,546) is a rare, autosomal recessive disorder due to loss of function mutations in the CYP19A1 gene, described in both genders with an estimated incidence below 1/1000000. While in female the clinical manifestations generally occur at birth or in early infancy, and mainly involve sexual characteristics, in men clinical signs of aromatase deficiency mostly occur in puberty and especially in late puberty, so that diagnosis is generally established after the second decade due to tall stature, unfused epiphyses and reduced bone mass. Here we review the available information concerning the skeletal and extraskeletal phenotype and the clinical management of bone health in patients with aromatase CYP19A1 gene mutations.

View Article and Find Full Text PDF

Skeletal muscle dysfunction (SMD), one of the extrapulmonary complications in patients with chronic obstructive pulmonary disease (COPD), considerably influences patient prognosis. Mitochondria regulates their dynamic networks through a mitochondria quality control (MQC) mechanism, involving mitochondrial biogenesis, mitochondrial dynamics, and mitophagy. The MQC is crucial for mitochondrial homeostasis and health, and disruption of it can lead to mitochondrial damage, which is a key factor in the structural and functional impairment of skeletal muscle in COPD.

View Article and Find Full Text PDF

Background: Apolipoprotein ε4 (APOE4) is a major risk factor for Alzheimer's disease (AD). APOE4 carriers display altered whole-body metabolism, including increased blood glucose and inuslin. Although conditions affecting whole-body metabolism like obesity and diabetes are AD risk factors, knowledge regarding the contribution of peripheral tissues to this effect is minimal.

View Article and Find Full Text PDF

Background: Midfacial aging involves skeletal changes, muscle weakening, and fat redistribution, resulting in volume loss, skin sagging, and deepened nasolabial folds. High-Intensity Facial Electrical Stimulation (HIFES) combined with Radiofrequency (RF) is a novel non-invasive method to address these changes by enhancing muscle mass and remodeling subcutaneous tissue.

Objectives: To assess the efficacy of HIFES and Synchronized RF in improving midfacial aesthetics, specifically muscle thickness, skin displacement, and facial volume.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!